{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T07:24:04Z","timestamp":1773473044947,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s11606-020-06167-5","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T22:02:20Z","timestamp":1602799340000},"page":"632-639","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Association Between Statins and Cancer Incidence in Diabetes: a Cohort Study of Japanese Patients with Type 2 Diabetes"],"prefix":"10.1007","volume":"36","author":[{"given":"Sadanori","family":"Okada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisao","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Soejima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisa","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mio","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naofumi","family":"Doi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Jinnouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Waki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izuru","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5574-3571","authenticated-orcid":false,"given":"Yoshihiko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"6167_CR1","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;139:e1082-e1143.","journal-title":"Circulation"},{"key":"6167_CR2","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315-2381.","journal-title":"Eur Heart J"},{"key":"6167_CR3","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2019. Diabetes Care. 2019;42:S103-S123.","DOI":"10.2337\/dc19-S010"},{"key":"6167_CR4","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1056\/NEJMoa1201735","volume":"367","author":"SF Nielsen","year":"2012","unstructured":"Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012;367:1792-1802.","journal-title":"N Engl J Med"},{"key":"6167_CR5","doi-asserted-by":"publisher","first-page":"470","DOI":"10.4103\/ijc.IJC_214_17","volume":"54","author":"MK Kim","year":"2017","unstructured":"Kim MK, Myung SK, Tran BT, Park B. Statins and risk of cancer: a meta-analysis of randomized, double-blind, placebo-controlled trials. Indian J Cancer 2017;54:470-477.","journal-title":"Indian J Cancer"},{"key":"6167_CR6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.4149\/gpb_2017045","volume":"36","author":"J Sopkova","year":"2017","unstructured":"Sopkova J, Vidomanova E, Strnadel J, Skovierova H, Halasova E. The role of statins as therapeutic agents in cancer. Gen Physiol Biophys 2017;36:501-511.","journal-title":"Gen Physiol Biophys"},{"key":"6167_CR7","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1016\/j.biopha.2018.09.122","volume":"108","author":"Y Ahmadi","year":"2018","unstructured":"Ahmadi Y, Karimian R, Panahi Y. Effects of statins on the chemoresistance-the antagonistic drug-drug interactions versus the anti-cancer effects. Biomed Pharmacother 2018;108:1856-1865.","journal-title":"Biomed Pharmacother"},{"key":"6167_CR8","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3892\/or.2015.3741","volume":"33","author":"AK Altwairgi","year":"2015","unstructured":"Altwairgi AK. Statins are potential anticancerous agents (review). Oncol Rep 2015;33:1019-1039.","journal-title":"Oncol Rep"},{"key":"6167_CR9","doi-asserted-by":"publisher","first-page":"e29849","DOI":"10.1371\/journal.pone.0029849","volume":"7","author":"JR Emberson","year":"2012","unstructured":"Cholesterol Treatment Trialists C, Emberson JR, Kearney PM, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One. 2012;7:e29849.","journal-title":"PLoS One"},{"key":"6167_CR10","first-page":"181","volume":"7","author":"MB May","year":"2016","unstructured":"May MB, Glode A. Novel uses for lipid-lowering agents. J Adv Pract Oncol 2016;7:181-187.","journal-title":"J Adv Pract Oncol"},{"key":"6167_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/bjc.2016.149","volume":"115","author":"A Wang","year":"2016","unstructured":"Wang A, Aragaki AK, Tang JY, et al. Statin use and all-cancer survival: prospective results from the Women\u2019s Health Initiative. Br J Cancer 2016;115:129-135.","journal-title":"Br J Cancer"},{"key":"6167_CR12","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.2337\/dc10-0666","volume":"33","author":"E Giovannucci","year":"2010","unstructured":"Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010;33:1674-1685.","journal-title":"Diabetes Care"},{"key":"6167_CR13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jdiacomp.2010.06.004","volume":"24","author":"H Noto","year":"2010","unstructured":"Noto H, Osame K, Sasazuki T, Noda M. Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan. J Diabetes Complications 2010;24:345-353.","journal-title":"J Diabetes Complications"},{"key":"6167_CR14","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1008862","volume":"364","author":"SR Seshasai","year":"2011","unstructured":"Emerging Risk Factors C, Seshasai SR, Kaptoge S, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829-841.","journal-title":"N Engl J Med"},{"key":"6167_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s13340-013-0121-3","volume":"4","author":"M Kasuga","year":"2013","unstructured":"Kasuga M, Ueki K, Tajima N, et al. Report of the JDS\/JCA Joint Committee on Diabetes and Cancer. Diabetology International 2013;4:81-96.","journal-title":"Diabetology International"},{"key":"6167_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/jdi.12645","volume":"8","author":"J Nakamura","year":"2017","unstructured":"Nakamura J, Kamiya H, Haneda M, et al. Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001-2010: report of the Committee on Causes of Death in Diabetes Mellitus. J Diabetes Investig 2017;8:397-410.","journal-title":"J Diabetes Investig"},{"key":"6167_CR17","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.2337\/dc18-0368","volume":"41","author":"S Okada","year":"2018","unstructured":"Okada S, Morimoto T, Ogawa H, et al. Effect of aspirin on cancer chemoprevention in Japanese patients with type 2 diabetes: 10-year observational follow-up of a randomized controlled trial. Diabetes Care 2018;41:1757-1764.","journal-title":"Diabetes Care"},{"key":"6167_CR18","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1001\/jama.2008.623","volume":"300","author":"H Ogawa","year":"2008","unstructured":"Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300:2134-2141.","journal-title":"JAMA"},{"key":"6167_CR19","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1161\/CIRCULATIONAHA.116.025760","volume":"135","author":"Y Saito","year":"2017","unstructured":"Saito Y, Okada S, Ogawa H, et al. Low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus: 10-year follow-up of a randomized controlled trial. Circulation 2017;135:659-670.","journal-title":"Circulation"},{"issue":"Suppl 2","key":"6167_CR20","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.lungcan.2004.07.998","volume":"45","author":"AJ Sasco","year":"2004","unstructured":"Sasco AJ, Secretan MB, Straif K. Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer 2004;45 Suppl 2:S3-9.","journal-title":"Lung Cancer"},{"key":"6167_CR21","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.2337\/dc14-0523","volume":"37","author":"W Zhao","year":"2014","unstructured":"Zhao W, Guan J, Horswell R, et al. HDL cholesterol and cancer risk among patients with type 2 diabetes. Diabetes Care 2014;37:3196-3203.","journal-title":"Diabetes Care"},{"key":"6167_CR22","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1152\/physrev.00030.2014","volume":"95","author":"EJ Gallagher","year":"2015","unstructured":"Gallagher EJ, LeRoith D. Obesity and diabetes: the increased risk of cancer and cancer-related mortality. Physiol Rev 2015;95:727-748.","journal-title":"Physiol Rev"},{"key":"6167_CR23","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1093\/annonc\/mdw410","volume":"27","author":"C Coyle","year":"2016","unstructured":"Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol 2016;27:2184-2195.","journal-title":"Ann Oncol"},{"key":"6167_CR24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/dme.13854","volume":"36","author":"E Ripamonti","year":"2019","unstructured":"Ripamonti E, Azoulay L, Abrahamowicz M, Platt RW, Suissa S. A systematic review of observational studies of the association between pioglitazone use and bladder cancer. Diabet Med 2019;36:22-35.","journal-title":"Diabet Med"},{"key":"6167_CR25","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/ijc.23191","volume":"122","author":"K Asano","year":"2008","unstructured":"Asano K, Kubo M, Yonemoto K, et al. Impact of serum total cholesterol on the incidence of gastric cancer in a population-based prospective study: the Hisayama study. Int J Cancer 2008;122:909-914.","journal-title":"Int J Cancer"},{"key":"6167_CR26","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1002\/ijc.24668","volume":"125","author":"H Iso","year":"2009","unstructured":"Iso H, Ikeda A, Inoue M, Sato S, Tsugane S, Group JS. Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. Int J Cancer 2009;125:2679-2686.","journal-title":"Int J Cancer"},{"key":"6167_CR27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2188\/jea.JE20100065","volume":"21","author":"N Nago","year":"2011","unstructured":"Nago N, Ishikawa S, Goto T, Kayaba K. Low cholesterol is associated with mortality from stroke, heart disease, and cancer: the Jichi Medical School Cohort Study. J Epidemiol 2011;21:67-74.","journal-title":"J Epidemiol"},{"key":"6167_CR28","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1503\/cmaj.071474","volume":"179","author":"X Yang","year":"2008","unstructured":"Yang X, So W, Ko GT, et al. Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. CMAJ 2008;179:427-437.","journal-title":"CMAJ"},{"key":"6167_CR29","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1158\/0008-5472.CAN-15-2613","volume":"76","author":"OF Kuzu","year":"2016","unstructured":"Kuzu OF, Noory MA, Robertson GP. The role of cholesterol in cancer. Cancer Res 2016;76:2063-2070.","journal-title":"Cancer Res"},{"key":"6167_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/hsz-2014-0194","volume":"396","author":"T Murai","year":"2015","unstructured":"Murai T. Cholesterol lowering: role in cancer prevention and treatment. Biol Chem. 2015;396:1-11.","journal-title":"Biol Chem."},{"key":"6167_CR31","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.2337\/dc09-0725","volume":"32","author":"X Yang","year":"2009","unstructured":"Yang X, So WY, Ma RC, et al. Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes Care 2009;32:1826-1832.","journal-title":"Diabetes Care"},{"key":"6167_CR32","doi-asserted-by":"publisher","first-page":"184","DOI":"10.2174\/1574892812666171129141211","volume":"13","author":"F Iannelli","year":"2018","unstructured":"Iannelli F, Lombardi R, Milone MR, et al. Targeting mevalonate pathway in cancer treatment: repurposing of statins. Recent Pat Anticancer Drug Discov 2018;13:184-200.","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"6167_CR33","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nrendo.2015.37","volume":"11","author":"X Yang","year":"2015","unstructured":"Yang X, Lee HM, Chan JC. Drug-subphenotype interactions for cancer in type 2 diabetes mellitus. Nat Rev Endocrinol 2015;11:372-379.","journal-title":"Nat Rev Endocrinol"},{"key":"6167_CR34","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1463-1326.2011.01551.x","volume":"14","author":"XL Yang","year":"2012","unstructured":"Yang XL, Ma RC, So WY, Kong AP, Xu G, Chan JC. Addressing different biases in analysing drug use on cancer risk in diabetes in non-clinical trial settings--what, why and how? Diabetes Obes Metab 2012;14:579-585.","journal-title":"Diabetes Obes Metab"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-020-06167-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-020-06167-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-020-06167-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T13:58:42Z","timestamp":1669211922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-020-06167-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["6167"],"URL":"https:\/\/doi.org\/10.1007\/s11606-020-06167-5","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"assertion":[{"value":"10 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Okada reports personal fees from Novo Nordisk, Mitsubishi Tanabe, Sumitomo Dainippon, Arkray, Bayer, Eli Lilly, Boehringer Ingelheim, Ono, AstraZeneca, Sanofi, and Takeda, outside the submitted work. Dr. Morimoto reports personal fees from AstraZeneca, Bayer, Daiichi Sankyo, Japan Lifeline, Kyocera, Mitsubishi Tanabe, Novartis, Pfizer, Asahi Kasei, Bristol-Myers Squibb, and Boston Scientific, outside the submitted work. Dr. Ogawa reports personal fees from MSD, Daiichi Sankyo, Ono, Mochida, AstraZeneca, Pfizer, Bristol-Myers Squibb, Mitsubishi Tanabe, Kyowa Kirin, Sanofi, and Medtronic, outside the submitted work. Dr. Soejima reports grants from Boehringer Ingelheim, outside the submitted work. Dr. Matsumoto has nothing to disclose. Dr. Sakuma reports personal fees from Enomoto Pharmaceutical, outside the submitted work. Dr. Nakayama reports personal fees from Bayer, Shionogi, Takeda, Daiichi Sankyo, Sanofi, Boehringer Ingelheim, Sumitomo Dainippon, Fujifilm Medical, Kowa, Pfizer, and Astellas, outside the submitted work. Dr. Doi reports personal fees from Daiichi Sankyo, Mitsubishi Tanabe, Takeda, Otsuka, Astellas, Boehringer Ingelheim, Abbott, Bayer, Medtronic, Pfizer, Kowa, MSD, and Actelion, outside the submitted work. Dr. Jinnouchi reports grants and personal fees from MSD, Boehringer Ingelheim, Novo Nordisk, Daiichi Sankyo, Takeda, Taisho Toyama, Astellas, Bayer, Sanofi, Sanwa Kagaku Kenkyusho, Eli Lilly, AstraZeneca; grants from Chugai, GlaxoSmithKline, Ono, Pfizer, Shionogi; personal fees from Abbott, Terumo, Kyowa Kirin, Teijin, Mitsubishi Tanabe, outside the submitted work. Dr. Waki reports grants and personal fees from Sanofi, AstraZeneca; personal fees from MSD, Astellas, Amgen Astellas BioPharma, Otsuka, Ono, Kowa, Kyowa Kirin, Novartis, Sanwa Kagaku Kenkyusho, Johnson & Johnson, Daiichi Sankyo, Taisho Toyama, Sumitomo Dainippon, Takeda, Mitsubishi Tanabe, Teijin, Eli Lilly, Novo Nordisk, Bayer, Pfizer, Boehringer Ingelheim, Abbott, outside the submitted work. Dr. Masuda reports personal fees from AstraZeneca, Ono, Takeda, Astellas, Bayer, Boehringer Ingelheim, Eli Lilly, Daiichi Sankyo, Kowa, Kyowa Kirin, MSD, Novartis, Shionogi, Mitsubishi Tanabe, outside the submitted work. Dr. Saito reports grants and personal fees from Bayer, Otsuka, Novartis, Ono, Mitsubishi Tanabe, Astellas, Asahi Kasei, Daiichi Sankyo, Sumitomo Dainippon, Fuji Yakuhin, Kowa, Kyowa Kirin, MSD, Sanofi, Takeda; grants from Terumo, Amgen Astellas BioPharma, Shionogi, Teijin, St. Jude Medical, Actelion, Boston Scientific, Chugai, Eisai, Medtronic, Nihon Medi-Physics, Zeria; personal fees from Boehringer Ingelheim, Pfizer, Taisho Toyama, Toa Eiyo, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}